Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Elysee Development Corp
V.ELC
Alternate Symbol(s):
ASXSF
Financial Services
Asset Management
Elysee Development Corp. is a Canada-based company, which is a diversified investment and venture capital firm. The Company is focused on publicly traded companies in the natural resource sector. The Company's investment activities are concentrated primarily on junior exploration and mining companies active in the gold and silver sectors as well as several technology companies. The Company’s investment portfolio consists of equity investments in small to medium-sized public and private companies, with a focus on precious metals, and includes investments in convertible debentures of various growth companies that provide security of capital and regular income along with participation in the potential for capital appreciation. Its investments cover a range of activities with a focus on natural resources and in particular the precious metals sector.
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
New Post
TSXV:ELC - Post by User
Elysee Development Corp
Bullboard Posts
(15)
•••
gnote1
X
View Profile
View Bullboard History
Comment by
gnote1
on Oct 31, 2020 11:29am
103 Views
Post# 31818507
RE:RE:All fine and dandy
RE:RE:All fine and dandy
MD&A and Financials are out on SEDAR with this notable mention.
SUBSEQUENT EVENTS
Subsequent to September 30, 2020 t
he Company declared a dividend of $0.01 per common share
Comment on this Post
Bullboard Posts
3 Mid-Sized Stocks to Consider This Season
Quantum eMotion leaps by 20 per cent after Becton Dickinson deal
Canada Nickel unveils second of seven resources planned by mid-2025
BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide
NervGen Pharma: Proof that NVG-291 works?
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
{{ dialogTitle }}
×
Reject Reason
{{ policy.description }}
{{reasonError}}
Additional Comments
{{feedbackError}}
{{buttonTitle}}
Cancel
{{submitMsg}}
Featured News Links
Do you want to stay ahead of the markets? See how DealRoom can help.